Type 1 Diabetes | CHOP Research Institute
 

Type 1 Diabetes

PETITE-T1D

PETITE-T1D

The purpose of this study is to evaluate the safety and pharmacokinetics (drug levels in the blood) of teplizumab in children less than 8 years old.

Medtronic 780G System

Medtronic 780G System

This study will evaluate the safety and effectiveness of the MiniMed 780G insulin pump system used in combination with the DS5 CGM in type 1 diabetic pediatric participants in a home setting.

Understanding Risk and Resilience in Minority Youth: Q&A With Diversity Fellow Alfonso L. Floyd, PhD

Published on
Jan 11, 2023
in Cornerstone Blog
Q&A With Diversity Fellow Alfonso L. Floyd, PhD
Diversity Fellow Alfonso Floyd, PhD, studies the impact of risk and resilience on the mental health of minority youth with type 1 diabetes.

CHOP Research Institute Scientific Symposium: Harnessing the Immune Response

Published on
Jun 2, 2022
in Cornerstone Blog
Scientific Symposium 2022: Harnessing the Immune Response
CHOP and Penn researchers discussed the latest findings about the mechanisms of immunity at the CHOP Research Institute 2022 Scientific Symposium.

Type 1 Diabetes, CZI Grant, Cystic Fibrosis, Mitochondrial Disease

Published on
Sep 3, 2021
in Cornerstone Blog
In the News: Diabetes, CZI Grant, Cystic Fibrosis, Mitochondrial Disease
This week’s In the News highlights two new studies, a new grant, the new director of the Cystic Fibrosis Center, and a physician’s new role.

PRONTO-PEDS: Ultra-Rapid Insulin Lispro in T1D

PRONTO-PEDS will test if a ultra-fast insulin product given before or immediately after meals improves glycemic control in children and teens with type 1 diabetes.

Teplizumab in New-Onset Type 1 Diabetes

Teplizumab in New-Onset Type 1 DiabetesTeplizumab in New-Onset Type 1 Diabetes

This is a study that investigates whether an IV medication (teplizumab) will slow or halt the progression of type 1 diabetes in children and adolescents (ages 8 - 17 years).

David R. Weber, MD, MSCE
David R. Weber

Dr. Weber is a clinical researcher focused on improving bone health in children. He is currently focused on investigating the effects of effects of type 1 diabetes and Duchenne muscular dystrophy on the skeleton. 

E-mail:
weberd [at] chop.edu

Researcher Studies How Microbes Help to Eclipse Autoimmune Risk Factors

Published on
May 28, 2020
in Cornerstone Blog
Gut Bacteria and Type 1 Diabetes
Michael Silverman, MD, PhD, is pursuing research to learn how gut bacteria may help signal genes to prevent type 1 diabetes.

Silverman Laboratory

Silverman Lab

The Silverman Lab investigates early-life modifiable factors influencing the development and function of the immune system and harnesses these factors to prevent autoimmune diabetes (T1D). The lab discovered that the major histocompatibility complex class II E molecule prevents T1D by shaping the intestinal microbiota early in life.